North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.
National Institute for Infectious Diseases "L. Spallanzani", 00161 Roma, Italy.
Viruses. 2022 Nov 10;14(11):2488. doi: 10.3390/v14112488.
The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen in the Omicron variant of concern and its sublineages, demanding the development of Omicron Spike-based vaccines. Herein, we review the evidence in animal models and topline results from ongoing clinical trials with such updated vaccines, discussing the pros and cons for their deployment.
迄今为止，获得授权的基于野生型 SARS-CoV-2 刺突蛋白的疫苗已经降低了 COVID-19 的严重程度，但需要定期加强针来对抗免疫的下降。正如在关注的奥密克戎变体及其亚谱系中所见，对疫苗诱导的免疫的免疫逃逸速度加快与刺突蛋白抗原转变有关，因此需要开发基于奥密克戎刺突蛋白的疫苗。在此，我们综述了这些更新的疫苗在动物模型中的证据和正在进行的临床试验的主要结果，讨论了它们部署的优缺点。
